C. Difficile

An analysis revealed that 29% exhibited reduced susceptibility to reduced vancomycin, underscoring the importance of enhanced monitoring of these strains to inform antibiotic prescribing practices.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.

Ferring presented new real-world data demonstrating that 73.3% of patients reported enhanced physical function and 86.7% experienced better mental well-being.

Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.

Timothy Ritter, MD, provides his insights on using the live biotherapeutic product and what both patients and clinicians can expect in terms of safety and efficacy.

The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.

To close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.

Members of the panel discuss when and where they tend to utilize fecal microbiota transplantation for recurrent C. difficile infections in clinical practice.

Peggy Lillis Foundation CEO Christian Lillis believes patients need a seat at the table so he is advocating for past patients to become ambassadors to be a voice to help shape treatment and also continue to raise awareness about the infection.

At this week’s ID Week, Ferring Pharmaceuticals shares results from its outpatient study examining its treatment, Rebyota, for the prevention of recurrence.

The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.

Healthcare workers receiving additional COVID-19 vaccine doses had fewer ongoing symptoms, a new test differentiates bacterial from viral infections, CDC reports 10 deaths linked to ongoing listeria outbreak, and more this week from Contagion.

This study highlights fidaxomicin’s advantages over vancomycin, including lower recurrence rates of CDI and higher sustained clinical responses.

Get caught up with the latest study information, feedback from people in the field, and news on the latest investigational therapies.

This week, a push for better care standards for C difficile, a survey shows low vaccination rates for respiratory viruses among Americans, Georgia achieves a reduction in chronic hepatitis C infections through collaborative efforts, and more.

The latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.

Study halted due to ineffective results, but the findings still provide valuable insights for future research and improve treatment strategies for those affected by CDI.

Cross-regional strains may spread more effectively in the community, highlighting the need for ongoing molecular surveillance to monitor their prevalence and detect potential changes.

A new study looked at Bacteroides thetaiotaomicron and C difficile infection (CDI) and their formation of symbiotic biofilms in the antibiotic's environment, and underscore the complexity of CDI prevention and the importance of considering gut microbiomes in treatment strategies.

Adults with type 2 diabetes taking metformin have a 13% to 21% lower risk of developing Long COVID or dying from COVID-19, recent analyses question the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new variants, and more this week from Contagion.

Jeanine Thomas, president and founder of MRSA Survivors Network, talks about her personal battle with osteomyelitis, her work as an advocate, and the need for data and awareness to bring it to the forefront again.

By analyzing 38 strains from patients, researchers identified clusters linked to frequent room changes, highlighting the need for improved infection control measures.

Matthew D. Sims, MD, PhD, FACP, FIDSA, discuss how antibiotics do not completely eliminate C. difficile infections, the drivers of recurrence, and new treatments that are addressing eubiosis and C. difficile spores.

This week, World AMR Congress interviews, Long COVID’s toll on the brain, e coli outbreak linked to lettuce, and more.

C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.